Dogwood Therapeutics, Inc.
NASDAQ:DWTXBiotechnology
+$0.04 today
- Market cap
- $51.12M
- Beta
- 1.76
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.84
Volume 0.12M
Average 0.09M
DWTX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Dogwood Therapeutics, Inc.NASDAQ: DWTX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $11.29M rose 53.2% year over year, ahead of the -53.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 34577.5% from the prior quarter. Over 3 fiscal years it compounded at +17.5% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +53.2% holds above the trailing-twelve-month pace of -53.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 7.28M USD
- Year-over-year change
- -56.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.28M | -56.4% |
| FY2024 | 2024-12-31 | 16.7M | +1344.5% |
| FY2023 | 2023-12-31 | 1.16M | -74.2% |
| FY2022 | 2022-12-31 | 4.49M | +4700.8% |
| FY2021 | 2021-12-31 | (97.6K) | — |
Financing Cash Flow vs competitors
How DWTX compares with its peers on the latest reported figures
- DWTX's LTM Mar 2026 financing cash flow of $11.2M is the largest of the 2 companies compared; the peer median is $3.84M.
- Its year-over-year change of -53.5% is the highest of 2, against a peer median of -77.0%.
- Over three fiscal years its annual growth of +17.5% compares with a peer median of +13.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.2M | -53.5% | +17.5% | — | |
| LTM Mar 2026 | $3.84M | -77.0% | +13.6% | — | |
| Peer median (excluding DWTX) | $3.84M | -77.0% | +13.6% | — | |
Competitors are the stored peer set for DWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.96M) | (12.25M) | (5.3M) | (12.35M) | (34.26M) |
| Depreciation & Amortization | 0 | 0 | 0 | 12.18K | 2.06K |
| Deferred Income Tax | 0 | 0 | 0 | (503) | 221.1K |
| Stock-Based Compensation | 322.88K | 582.66K | 619.97K | 476.02K | 355.64K |
| Change in Working Capital | (52.19K) | 197.38K | (194.45K) | (581.27K) | (133K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 270.01K | 219.3K | (461.25K) | 219.89K | (532.61K) |
| Other Working Capital | (322.2K) | (21.92K) | 266.81K | (801.16K) | 399.6K |
| Other Non-Cash Items | 0 | 0 | 0 | 3.65M | 18.19M |
| Operating Cash Flow | (15.69M) | (11.47M) | (4.87M) | (8.79M) | (15.62M) |
| Capital Expenditures | 0 | (3) | 0 | 5 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 3.76M | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 3.76M | 0 |
| Debt Repayment | 0 | 0 | 0 | 15.32M | 3M |
| Common Stock Issued | 0 | 4.49M | 1.16M | 1.38M | 4.34M |
| Common Stock Repurchased | (295.17K) | 0 | 0 | (351) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 197.56K | 0 | 0 | 0 | (53.81K) |
| Financing Cash Flow | (97.6K) | 4.49M | 1.16M | 16.7M | 7.28M |
| Effect of Forex Changes | 0 | 0 | 0 | (144.59K) | 10.64K |
| Net Change in Cash | (15.79M) | (6.98M) | (3.71M) | 11.53M | (8.32M) |
| Free Cash Flow | (15.69M) | (11.47M) | (4.87M) | (8.79M) | (15.62M) |
Dogwood Therapeutics, Inc.
NASDAQ:DWTX
Intrinsic Alpha fair value
Locked
Current Price
$1.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.